Published in
American Society of Hematology, Blood, 26(125), p. 4032-4041, 2015
DOI: 10.1182/blood-2014-11-610329
Links
- ORCID
- ORCID
- American Society of Hematology | PDF
- [eprints.soton.ac.uk] | PDF
- [eprints.soton.ac.uk] | PDF
Tools
The PI3K/mTOR inhibitor PF-04691502 induces apoptosis and inhibits microenvironmental signaling in CLL and the Eµ-TCL1 mouse model
Journal article published in 2015 by
Matthew D. Blunt 
,
Matthew J. Carter,
Marta Larrayoz ,
Lindsay D. Smith,
Maria Aguilar-Hernandez,
Kerry L. Cox,
Thomas Tipton,
Mark Reynolds,
Sarah Murphy,
Elizabeth Lemm,
Samantha Dias,
Andrew Duncombe,
Jonathan C. Strefford,
Peter W. M. Johnson,
Francesco Forconi
and other authors.
,
Matthew J. Carter,
Marta Larrayoz ,
Lindsay D. Smith,
Maria Aguilar-Hernandez,
Kerry L. Cox,
Thomas Tipton,
Mark Reynolds,
Sarah Murphy,
Elizabeth Lemm,
Samantha Dias,
Andrew Duncombe,
Jonathan C. Strefford,
Peter W. M. Johnson,
Francesco Forconi
and other authors.
This paper is made freely available by the publisher.
Full text: Download
Preprint: archiving forbidden
Published version:
archiving forbidden
Data provided by 
Abstract
Key Points PF-04691502 induces potent apoptosis in CLL cells and suppresses prosurvival anti–immunoglobulin M signaling and CXCL12-induced migration. PF-04691502 displays powerful antitumor effects in vivo in the Eμ-TCL1 mouse model.